The Quiet AI Revolution Happening Outside Silicon Valley

The companies generating the most transformative value from artificial intelligence are not building AI — they are using it to reinvent industries that have existed for decades

Audio summary: https://youtu.be/_tULJSg1nB4

Sign up for my Substack daily AI newsletter here.

See my AI Training course portfolio for corporate Business Leaders here.

Article link: https://open.substack.com/pub/johanosteyn/p/the-quiet-ai-revolution-happening?r=73gqa&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

Follow me on LinkedIn: https://www.linkedin.com/in/johanosteyn/

There is a persistent assumption in public discourse about AI that the biggest winners will be the companies closest to the technology itself — the model builders, the chip makers, the platform providers. That assumption is increasingly wrong. The companies generating the most durable and transformative value from artificial intelligence are often the ones we least expect: pharmaceutical giants, agricultural businesses, logistics operators, and financial institutions with decades of domain knowledge, proprietary data, and real-world problems that actually matter. The AI revolution is real. But its most important chapter is not being written in Silicon Valley.

CONTEXT AND BACKGROUND

Writing for Barchart, financial journalist Sushree Mohanty has highlighted the case of Eli Lilly as a compelling illustration of this shift. Lilly, a pharmaceutical company with roots stretching back more than a century, has used AI to build what is now one of the largest clinical pipelines in its history — 36 active Phase 3 programmes, 14 new late-stage trials recently initiated, and revenue that rose 45% year-over-year to $65.2 billion in 2025, with projections of up to $83 billion in 2026. Lilly’s collaboration with Nvidia to build a co-innovation AI lab, its TuneLab initiative opening AI access to the broader biotech ecosystem, and its $55 billion in manufacturing investment since 2020 are not the actions of a company dabbling in technology. They are the actions of a business that has understood, earlier than most, that AI is not a product to be bought but a capability to be built into the core of how the organisation operates.

The pharmaceutical sector is not alone. Deloitte’s 2026 State of AI in the Enterprise report found that 78% of organisations now use AI in at least one business function, up from 55% just one year earlier, with industries including manufacturing, logistics, financial services, and agriculture all recording accelerating adoption.

McKinsey Global Institute projects that generative AI could unlock between $60 billion and $110 billion in annual economic value for the pharmaceutical and medical products industries alone. The World Trade Organisation's World Trade Report 2025 goes further, projecting that AI could boost global trade value by 34% to 37% by 2040 — driven by lower trade costs, the rapid growth of AI-enabled services, and stronger productivity gains in the sectors most integrated into international trade. These are not technology companies generating these projections. They are the industries that feed, move, heal, and finance the world.

INSIGHT AND ANALYSIS

The reason non-technology companies are emerging as AI’s most powerful beneficiaries is not difficult to understand. AI rewards depth. The more domain-specific, proprietary, and historically accumulated the data, the more powerful the models that can be built from it. A pharmaceutical company with decades of clinical trial data, biological research, and compound libraries has assets that no technology start-up can replicate. A logistics company with years of route optimisation data, demand signals, and supplier behaviour patterns holds a competitive advantage that AI can amplify into something formidable. The technology itself is increasingly available. What remains scarce, and therefore valuable, is the knowledge required to deploy it meaningfully.

The pharmaceutical industry illustrates this most vividly. As BioSpace has reported, companies like Lilly, Pfizer, and Bristol Myers Squibb are not competing to build frontier AI models — they are competing to embed AI into every workflow across discovery, clinical trials, manufacturing, and regulatory submissions. Pfizer has paired AI engineers directly with scientists across its R&D organisation, planning to spend $11 billion on R&D activities in 2026. Drug Target Review notes that 2026 will see the first truly large-scale test of whether AI can improve clinical success rates beyond the pharmaceutical industry’s historical 90% failure rate — a milestone that will define the technology’s credibility in this sector for the next decade.

What is true in pharmaceuticals is equally true across sectors. PwC’s 2026 AI predictions note that in financial services, AI agents are already handling invoice processing, purchase order matching, reconciliation, and anomaly detection — freeing human expertise for higher-value work in revenue generation, vendor negotiation, and strategic planning. In agriculture, precision farming tools are analysing soil conditions, weather patterns, and crop health at a granularity that was previously impossible. In logistics, predictive maintenance, autonomous route optimisation, and AI-driven demand forecasting are reshaping supply chains that underpin the entire global economy. In each of these cases, the AI advantage belongs not to those who built the tools, but to those with the knowledge, data, and execution capacity to use them.

IMPLICATIONS

For business leaders in South Africa and across Africa, the lesson from Eli Lilly and its peers is one that should prompt genuine reflection. The question is not whether your organisation operates in a technology sector. The question is whether you have a strategy for embedding AI into the domain expertise that already makes your business valuable. A mining company with decades of geological data, a retailer with years of customer behaviour patterns, an agricultural cooperative with generations of local farming knowledge — all of these represent AI assets that technology companies cannot buy or replicate.

The organisations that will win the next decade are those that recognise this and act on it deliberately, rather than waiting for a technology partner to bring them a solution.

The Deloitte report also cautions that while twice as many leaders as last year are reporting transformative AI impact, only 34% are truly reimagining their businesses rather than simply optimising existing processes. That gap — between incremental efficiency and genuine reinvention — is where the real competitive battles of the next decade will be fought. Eli Lilly did not merely add AI to its existing drug development process. It rebuilt the process around AI’s capabilities, and the financial results have been extraordinary.

CLOSING TAKEAWAY

The narrative that AI belongs to technology companies is one of the most consequential misconceptions in business today. The technology provides the tools. The competitive advantage comes from the knowledge, data, and domain depth that established industries have spent decades accumulating. Healthcare is proving it. Agriculture is beginning to prove it. Logistics and financial services will prove it next. For business leaders in Africa and beyond, the message is direct: you do not need to be a technology company to be an AI winner. You need to understand what you already know, commit to embedding AI into the heart of how you use that knowledge, and be willing to redesign your organisation around the possibilities that combination unlocks. The quiet revolution is already underway. The only question is who will be part of it.

Author Bio: Johan Steyn is a prominent AI thought leader, speaker, and author with a deep understanding of artificial intelligence’s impact on business and society. He served as a working group member contributing recommendations toward South Africa’s national AI strategy, an initiative by the National Advisory Council on Innovation, the Council for Scientific and Industrial Research, the Human Sciences Research Council, and the Department of Science and Innovation. He is passionate about ethical AI development and its role in shaping a better future. Find out more about Johan’s work at https://www.aiforbusiness.net